Blinatumomab
Precursor B-Cell Acute Lymphoblastic Leukemia
Amgenmonoclonal_antibodyPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Precursor B-Cell Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE First Affiliated Hospital of Zhejiang University | Phase 2 | B |
PREDNISONE TABLETS First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
Olverembatinib First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
Daunorubicin First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
Idarubicine First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
Zofran Fate Therapeutics | Phase 1 | CC |
Bendamustine Fate Therapeutics | Phase 1 | CC |
ft819 Fate Therapeutics | Phase 1 | CC |
Same molecule, other indications
Blinatumomab is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →